Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

Loren Laine(University of Southern California), Sean Curtis(Merck & Co., Inc., Rahway, NJ, USA (United States)), Byron Cryer(Dallas VA Medical Center), Amarjot Kaur(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher P. Cannon(Brigham and Women's Hospital)
The Lancet
February 1, 2007
10.1016/s0140-6736(07)60234-7
Cited by 250

Abstract

Related Papers

Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Francesca Catella-Lawson, Muredach P. Reilly, Shiv Kapoor et al.|New England Journal of Medicine|2001|1.4k
Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs
Fred E. Silverstein, David Y. Graham, John R. Senior et al.|Annals of Internal Medicine|1995|1.1k
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs
IA Reilly, GA FitzGerald|Blood|1987|374
Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers
Anne Van Hecken, Jules I. Schwartz, Marleen Depré et al.|The Journal of Clinical Pharmacology|2000|355
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study
Gurkirpal Singh, John G. Fort, Jay L. Goldstein et al.|The American Journal of Medicine|2006|335